These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30916752)

  • 1. Unique Origins of Modern Opioid Marketing and the Link to the Opioid Epidemic: A Historical Perspective.
    Hooten KM; Hooten WM
    Pain Med; 2019 Aug; 20(8):1638-1639. PubMed ID: 30916752
    [No Abstract]   [Full Text] [Related]  

  • 2. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 3. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 4. A historical perspective of pharmaceutical promotion and physician education.
    Podolsky SH; Greene JA
    JAMA; 2008 Aug; 300(7):831-3. PubMed ID: 18714063
    [No Abstract]   [Full Text] [Related]  

  • 5. The Neurontin legacy--marketing through misinformation and manipulation.
    Landefeld CS; Steinman MA
    N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
    [No Abstract]   [Full Text] [Related]  

  • 6. Preying on Prescribers (and Their Patients) - Pharmaceutical Marketing, Iatrogenic Epidemics, and the Sackler Legacy.
    Podolsky SH; Herzberg D; Greene JA
    N Engl J Med; 2019 May; 380(19):1785-1787. PubMed ID: 30969504
    [No Abstract]   [Full Text] [Related]  

  • 7. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 8. Purdue Pharma to plead guilty and pay $8.3bn over opioid marketing.
    Dyer O
    BMJ; 2020 Oct; 371():m4103. PubMed ID: 33093019
    [No Abstract]   [Full Text] [Related]  

  • 9. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 10. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP; Kesselheim AS
    J Law Med Ethics; 2018 Jun; 46(2):552-554. PubMed ID: 30146990
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 12. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
    Sharfstein JM; Charo A
    JAMA; 2015 Nov; 314(17):1795-6. PubMed ID: 26367520
    [No Abstract]   [Full Text] [Related]  

  • 13. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
    Roehr B
    BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
    [No Abstract]   [Full Text] [Related]  

  • 14. Direct-to-consumer prescription drug advertising: history, regulation, and issues.
    Huh J; DeLorme DE; Reid LN; An S
    Minn Med; 2010 Mar; 93(3):50-2. PubMed ID: 20429178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The limits of free speech.
    Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 17. Reforming direct-to-consumer advertising.
    Liang BA; Mackey T
    Nat Biotechnol; 2011 May; 29(5):397-400. PubMed ID: 21552236
    [No Abstract]   [Full Text] [Related]  

  • 18. Boon for drugmakers. Victory on off-label marketing called 'new era'.
    Carlson J
    Mod Healthc; 2012 Dec; 42(50):12. PubMed ID: 23323336
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharma fines increase, but the pain is not felt on Wall Street.
    Matthews S
    Nat Med; 2013 Jan; 19(1):5. PubMed ID: 23295992
    [No Abstract]   [Full Text] [Related]  

  • 20. [The development of the Japanese pharmaceutical industry (Part 8) - the change of opium alkaloid opioid analgesics in Japanese pharmaceutical companies.].
    Takehara J
    Yakushigaku Zasshi; 2005; 40(1):34-40. PubMed ID: 16217905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.